ARA-290 (Cibinetide)

ARA-290 is the development code of a synthetic peptide whose international nonproprietary name is cibinetide. It is also found in the literature as pyroglutamate helix B surface peptide (pHBSP). The molecule is short by pharmaceutical standards: 11 amino acids, with the sequence Pyr-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser, a molecular formula of C₅₁H₈₄N₁₆O₂₁ and a molecular weight of approximately 1257.33 g/mol. The first residue is a pyroglutamate, a cyclized form of glutamic acid.

The sequence is not arbitrary. It reproduces a specific surface of erythropoietin (EPO), the hormone best known for driving red blood cell production. Researchers had long observed that EPO also appears to protect tissues under stress in ways that are difficult to explain through erythropoiesis alone. Work published in the Proceedings of the National Academy of Sciences in 2008 reported that these tissue-protective activities could be mimicked by small nonerythropoietic peptides reproducing part of the three-dimensional structure of EPO, and specifically pointed to the surface of helix B as the relevant region.

ARA-290 is the clinical candidate that came out of that line of reasoning. What makes it unusual among peptides discussed in online communities is that it did not stop at the animal stage. It went through a series of registered, placebo-controlled human trials, mainly in sarcoidosis-associated small fiber neuropathy, and the results were published in peer-reviewed journals. That is a higher bar than most research peptides clear.

It is equally important to state the boundary of that record. Cibinetide is not approved by the United States Food and Drug Administration or by the European Medicines Agency for any indication. The published human data come from phase 2 studies with small sample sizes and short follow-up. This guide is educational and does not constitute medical advice, nor does it suggest that anyone should obtain or administer this peptide.

The pharmacological premise of ARA-290 rests on the idea that EPO signals through more than one receptor configuration. The classical erythropoietic signal travels through a homodimer of the EPO receptor (EPOR), two identical subunits that respond to circulating EPO and drive the maturation of red blood cell precursors in the bone marrow. This is the pathway exploited by recombinant EPO in anemia of chronic kidney disease.

A second configuration has been proposed for the tissue-protective effects. In a 2016 review in PAIN Reports, Dahan and colleagues described the innate repair receptor (IRR) as a heteromer assembling the EPO receptor together with the beta common receptor (CD131), a subunit shared with several cytokine receptors. According to that model, engaging the IRR activates anti-inflammatory and tissue-repair pathways simultaneously, which is a different biological output from stimulating erythropoiesis.

Two features of this model matter for interpreting the clinical work. First, the IRR is described as being assembled and expressed mainly in tissues that are already injured or metabolically stressed, rather than being constitutively available everywhere. If that holds, an IRR agonist would act preferentially where damage is ongoing, which is a plausible explanation for why investigators looked for effects in damaged nerve fibers rather than in healthy tissue. Second, the receptor identity predicts what should not happen: a selective IRR agonist should not meaningfully stimulate the bone marrow.

This mechanistic account is coherent, well cited, and still a model rather than settled fact. The composition and signaling of the innate repair receptor remain an active research question, and the role of the beta common receptor in EPO-mediated protection continues to be debated in the literature. Readers should treat the mechanism as the working hypothesis that guided the trials, not as proof that the trials succeeded.

The design logic is structural. The region of EPO that binds the classical homodimeric receptor and the region that reproduces the helix B surface are not the same. By synthesizing only the 11 residues corresponding to the helix B surface, the developers aimed to keep the repair-associated signal and discard the erythropoietic one. The 2008 PNAS report that introduced these peptides describes them explicitly as nonerythropoietic while retaining tissue-protective activity in experimental models.

This separation is the central selling point of the molecule from a drug development standpoint, and it addresses a real clinical problem. Recombinant EPO and related erythropoiesis-stimulating agents carry recognized hematological and cardiovascular risks when red cell mass is pushed upward, which constrains any attempt to use EPO itself as a tissue-protective agent at high doses. A peptide that engages repair signaling without that constraint would, in principle, allow a different risk profile.

In the published human trials, investigators monitored clinical and laboratory parameters and did not report hematological safety signals. The 2012 randomized, double-blind pilot study in Molecular Medicine stated that no safety concerns were raised by clinical or laboratory assessments over four weeks of dosing in sarcoidosis patients. The later phase 2b trial reported no significant safety issues in any treatment group.

One caution deserves emphasis. The absence of an erythropoietic effect is not the same thing as the absence of risk. A molecule that modulates inflammatory signaling could in principle have consequences that short trials in small populations are not designed to detect, for example on immune surveillance or on tissue remodeling over long periods. Nothing in the published record establishes long-term safety, and no published trial followed participants for more than a few months.

The most developed human program for cibinetide targeted small fiber neuropathy associated with sarcoidosis, a condition in which thin unmyelinated and lightly myelinated nerve fibers are lost, producing burning pain, abnormal temperature sensation and autonomic symptoms. Conventional options are limited, which is part of why an agent claiming nerve fiber regeneration attracted attention.

The first published study was a randomized, double-blind pilot trial in Molecular Medicine in 2012. Twenty-two sarcoidosis patients with symptoms of small fiber neuropathy received either ARA-290 at 2 mg intravenously three times weekly (12 patients) or placebo (10 patients) for four weeks. The authors reported a significant improvement at week 4 in the Small Fiber Neuropathy Screening List score versus placebo, along with changes in the pain and physical functioning dimensions of the SF-36 questionnaire, and no safety concerns on clinical or laboratory assessment.

A second blinded, placebo-controlled trial published in Molecular Medicine in 2013 moved to daily subcutaneous dosing for 28 days. Beyond patient-reported symptom improvement, the authors reported a significant increase in corneal small nerve fiber density, changes in cutaneous temperature sensitivity, and an increase in exercise capacity measured by the 6-minute walk test. Daily administration of 4 mg subcutaneously was described as well tolerated, with no serious adverse events during dosing or during the follow-up period.

The largest published study is the phase 2b trial reported in Investigative Ophthalmology and Visual Science in 2017. It enrolled 64 subjects with sarcoidosis-associated small nerve fiber loss and neuropathic pain, randomized to 28 days of subcutaneous cibinetide at 1 mg, 4 mg or 8 mg daily, or placebo. The primary endpoint was corneal nerve fiber area measured by corneal confocal microscopy. A significant increase versus placebo was observed for the 4 mg dose, corresponding to roughly a 23 percent increase from baseline, and the authors also reported a significant increase in skin intraepidermal GAP-43 positive nerve fiber length, a marker of regenerating fibers. No significant safety issues were observed in any treatment group.

These dosing figures are reported here only to describe what the trials tested. They are not guidance, and nothing in this article should be read as a protocol. A dose-response that peaks at an intermediate dose, as seen in the phase 2b trial, is itself a reason for caution rather than a reason to extrapolate.

The second clinical line of inquiry was metabolic. A study published in Molecular Medicine in 2014 examined ARA-290 in patients with type 2 diabetes. Participants self-administered 4 mg subcutaneously daily, or placebo, for 28 days, and were then followed for a further month without dosing, for a total observation period of 56 days.

The authors reported that subjects receiving ARA-290 showed improvement in HbA1c and in lipid profiles across the 56-day observation period, and that neuropathic symptoms assessed by the PainDetect questionnaire improved significantly in the ARA-290 group. They also reported that the regimen was not associated with significant drug-related adverse events. Their stated conclusion was that the peptide may benefit both metabolic control and neuropathy in type 2 diabetes and deserved continued clinical evaluation.

This is the origin of the frequently repeated claim that ARA-290 addresses diabetic neuropathy. The claim needs framing. The study measured a patient-reported neuropathic symptom questionnaire in a small type 2 diabetes population over four weeks of dosing. It was not a dedicated, adequately powered trial in diagnosed diabetic peripheral neuropathy with hard clinical endpoints, and it was not replicated in a larger phase 3 program.

A different diabetic complication was tested with a clearly negative primary result. A phase 2 trial published in the Journal of Clinical Medicine in 2020 investigated cibinetide in diabetic macular edema. Nine patients were recruited and eight completed a 12-week course of 4 mg daily subcutaneous self-administration. Visual acuity, retinal thickness, retinal sensitivity and tear production did not improve on average. The authors reported that the course was safe, with no serious adverse events or reactions and no anti-cibinetide antibodies detected, while noting that some individual participants showed changes in central retinal thickness, tear production, diabetic control and albuminuria.

Taken together, the diabetes work is genuinely mixed. One small trial produced encouraging metabolic and symptom signals, and another small trial in a different diabetic complication missed its efficacy targets while confirming tolerability. Mixed early-phase results are normal in drug development. They are not a basis for concluding that the peptide works.

Animal work underpins and extends the human program. A study in Molecular Pain in 2014 examined ARA-290 in a rat model of neuropathic pain. The authors reported long-term relief of neuropathic pain coupled with suppression of the spinal microglia response, linking the behavioral effect to a reduction in neuroinflammatory activation in the spinal cord rather than to classical analgesia.

A separate team reported in PLoS ONE in 2014 that an EPO-derived nonerythropoietic peptide ameliorated experimental autoimmune neuritis, an animal model of inflammatory peripheral nerve disease, through inflammation suppression and tissue protection, with improved nerve regeneration and remyelination. This is consistent with the broader claim that the molecule acts on the inflammatory environment surrounding damaged nerves.

Other preclinical directions have included organ protection in models of ischemic and inflammatory injury, and the survival of transplanted pancreatic islets. The islet interest is reflected in the regulatory record: the European Medicines Agency granted cibinetide an orphan designation for prevention of graft loss in pancreatic islet transplantation (EU/3/16/1721). Preclinical plausibility and a regulatory designation are both a long way from demonstrated clinical benefit.

Animal models of neuropathy and inflammation translate poorly to human disease as a general rule, which is why the distinction between preclinical and clinical evidence runs through this entire guide. Readers who want the broader principle behind that caution will find it discussed in our overview of peptides studied in inflammation, where the same gap appears across most of the field.

Honest grading of the ARA-290 evidence base lands in an uncomfortable middle. On the positive side, the molecule has a defined structure, a stated mechanistic hypothesis, randomized placebo-controlled human trials, prespecified endpoints, and results published in indexed peer-reviewed journals. Compared with peptides whose entire reputation rests on rodent studies and user reports, that is a substantially stronger file.

On the limiting side, every published human trial is small. The largest randomized 64 subjects. Dosing periods were 28 days in the sarcoidosis and type 2 diabetes studies and 12 weeks in the macular edema study. No phase 3 results have been published, and the clinical program does not appear to have advanced to confirmatory trials. Short, small, early-phase studies routinely produce signals that later fail to replicate.

The endpoint choice also deserves scrutiny. The phase 2b primary endpoint was corneal nerve fiber area, a structural surrogate measured by corneal confocal microscopy. The investigators themselves published methodological work in Scientific Reports in 2018 arguing that nerve fiber area adds information beyond conventional density measures and can help assess therapeutic response. That is a reasonable scientific argument, and it is also a reminder that a change in a surrogate imaging metric is not by itself proof of durable clinical benefit for a patient.

Finally, note who conducted the work. The clinical trials and much of the supporting science involved authors affiliated with or funded by the sponsor developing the molecule. This is standard in pharmaceutical development and does not invalidate the data, but independent replication by unaffiliated groups is an element the file currently lacks. Overall, ARA-290 is best described as a mechanistically interesting investigational peptide with promising but unconfirmed phase 2 results.

The tolerability picture in the published trials is consistent, and consistently limited by scale. The 2012 pilot study reported that patients tolerated repeated intravenous infusions without adverse events noted by study personnel or self-reported, and that no safety concerns arose from clinical or laboratory assessments. The 2013 trial described daily 4 mg subcutaneous administration as well tolerated, with no serious adverse events during dosing or follow-up.

The phase 2b trial reported no significant safety issues in any of the four treatment groups across 28 days. The type 2 diabetes trial reported no significant drug-related adverse events over the 56-day observation period. The diabetic macular edema trial added an immunological datapoint: over 12 weeks of daily subcutaneous administration, no serious adverse events or reactions were observed and no anti-cibinetide antibodies were detected, which is a relevant consideration for any peptide given repeatedly.

What this record cannot tell us is more important than what it can. A few hundred participants exposed for four to twelve weeks cannot characterize uncommon adverse events, cannot establish safety in pregnancy, in children, in renal or hepatic impairment, or alongside other medications, and cannot speak to outcomes over months or years. Any statement that ARA-290 is safe, without those qualifiers, misrepresents the evidence.

A separate category of risk has nothing to do with the molecule itself. Material sold online as ARA-290 is not manufactured to pharmaceutical standards, is not subject to regulatory oversight of identity, purity, endotoxin content or sterility, and may not contain what the label claims. The general problem of product quality and self-administration risk is covered in our article on whether peptides are safe. If you are considering anything in this category, discuss it with a qualified healthcare professional first.

Cibinetide is not approved as a medicine by the FDA, the EMA, or any comparable major regulator. It has no marketing authorization for sarcoidosis-associated small fiber neuropathy, for diabetic neuropathy, for macular edema, or for any other indication. It remains an investigational compound.

It does hold orphan designations, which are frequently misreported online as approvals. In the European Union, cibinetide received orphan designation for the treatment of sarcoidosis (EU/3/13/1191) and for prevention of graft loss in pancreatic islet transplantation (EU/3/16/1721). In the United States, the sponsor announced FDA orphan drug designation for ARA-290 in sarcoidosis in July 2016, having previously obtained US orphan drug and fast track designations for neuropathic pain in patients with sarcoidosis.

An orphan designation is an incentive framework for developing products for rare conditions. It provides regulatory and commercial advantages such as fee reductions, protocol assistance and market exclusivity if approval is eventually granted. It says nothing about whether a product works, and designations can later be withdrawn at the sponsor's request or when a development program stops. A fast track designation similarly concerns the speed of regulatory interaction, not the strength of the evidence.

Legal status for individuals varies considerably by jurisdiction. In most markets, including the United States and the European Union, unapproved peptides of this kind are sold only as materials labeled for laboratory research use and are not legal to market or supply for human use. Possession, importation and supply rules differ from country to country, and competitive athletes face a further layer: substances affecting tissue repair and growth factor pathways fall under anti-doping scrutiny, so any athlete should verify current World Anti-Doping Agency prohibited and monitored lists rather than assume a peptide is permitted.

ARA-290 is often grouped with repair-oriented peptides, but its profile is distinct on two counts. The first is receptor specificity. Rather than a broad claim about tissue healing, cibinetide has a named molecular target hypothesis, the EPOR and CD131 heterodimer, with a clear structural rationale for why it should not reproduce the erythropoietic effect of its parent hormone. The second is the evidence stage reached: registered, randomized, placebo-controlled human phase 2 trials with prespecified structural endpoints.

That is a different situation from BPC-157, where the literature is dominated by preclinical rodent work with no published phase 3 human trials, and where the proposed mechanisms are multiple and less precisely defined. It also differs from thymosin alpha-1, which has a long immunomodulatory research history and regulatory approval in some jurisdictions for specific indications, placing it on a different regulatory footing again.

The comparison cuts both ways. Having reached phase 2 means ARA-290 has been tested more rigorously than most peptides in circulation. It also means the molecule has been exposed to the stage where candidates most often fail, and it has not yet produced the confirmatory evidence that would normally follow a positive phase 2b result. Reaching phase 2 and stopping there is a meaningful piece of information in its own right.

For readers mapping the field, the useful takeaway is not a ranking but a method: ask what receptor is targeted, what human trials exist, how many participants were studied, for how long, what endpoint was measured, and who funded the work. Applied to ARA-290, that method yields a clear answer. The science is interesting, the human data are real but preliminary, and the regulatory status is unambiguous.

Medical disclaimer: this article is for educational purposes only and does not provide dosing information, protocols, or medical advice. ARA-290 is a research peptide that is not approved for human use. Nothing here should be used to make decisions about your health. Consult a qualified healthcare professional for any medical question or before considering any investigational substance.